Hutchmed's (HKG:0013) Tagrisso and Orpathys combination showed a "favorable" response during a phase 2 trial for epidermal growth factor receptor-mutated non-small cell lung cancer.
Orpathys and Tagrisso are MET tyrosine kinase inhibitors, according to a Wednesday filing with the Hong Kong Exchange.
Shares increased 1% during Wednesday's trading.
Price (HKD): $30.40, Change: $+0.40, Percent Change: +1.33%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。